EirGen Pharma has agreed to sell its Sterile Fill Finish capability to Horizon Therapeutics plc. Within the sale is included the Sterile Fill Finish technology and the EirGen Pharma Building at Butlerstown, Waterford. Employees supporting the Fill Finish capability will transfer to Horizon Therapeutics as part of the operational change.
CEO of EirGen Pharma Damien Burke elaborated on the implications of this sale: “This is a progressive move for EirGen Pharma, Horizon Therapeutics and Waterford. It facilitates the expansion of our global Oral Solid Dose portfolio, will allow our Sterile Fill Finish team to be successful within a Global Fill Finish operation and brings additional career opportunities for both companies within the Life Sciences industry to Waterford.”
EirGen Pharma, with its parent company OPKO Health is fully invested in supporting the growth and development of its core EirGen business in Waterford, consisting of Oral Solid Dose technology for R&D and Commercial supply to global markets from EirGen’s facility at Westside Business Park in Waterford City. EirGen has and will continue to receive government support through IDA Ireland in the development of its unique R&D capability.
The EirGen Leadership team is fully committed to engaging with the extended Sterile Fill Finish team to ensure a supportive transition over the coming weeks. The EirGen Leadership team is also committed to supporting Horizon Therapeutics throughout the transition period and extends a warm welcome to them to the region.